Back to top
more

Merck & Co. (MRK)

(Delayed Data from NYSE)

$98.05 USD

98.05
29,274,391

-1.47 (-1.48%)

Updated Dec 20, 2024 04:03 PM ET

After-Market: $98.22 +0.17 (0.17%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.35%
2Buy18.11%
3Hold9.74%
4Sell5.34%
5Strong Sell2.80%
S&P50011.41%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 47% (131 out of 249)

Industry: Large Cap Pharmaceuticals

Zacks News

Biotech Stock Roundup: FOLD Settles Patent Dispute, Updates From EDIT & More

FOLD and EDIT are in the spotlight following patent dispute settlement news and strategic updates, respectively.

Analysts Estimate Merck (MRK) to Report a Decline in Earnings: What to Look Out for

Merck (MRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Summit Therapeutics Stock: Sell or Hold Before Q3 Earnings?

Devoid of any marketed drug in its portfolio, investors will likely focus on SMMT's pipeline updates when it reports third-quarter results this month.

Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know

Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Summit Stock Skyrockets Nearly 700% YTD: Time to Sell or Hold?

The rally in SMMT stock is driven by encouraging updates on its oncology candidate, which has the potential to become the next standard of care in the NSCLC space.

Merck (MRK) Advances While Market Declines: Some Information for Investors

Merck (MRK) reachead $106.64 at the closing of the latest trading day, reflecting a +0.28% change compared to its last close.

The Zacks Analyst Blog Highlights Visa, Netflix, Merck and Hovnanian

Visa, Netflix, Merck and Hovnanian are included in this Analyst Blog.

Mark Vickery headshot

Top Research Reports for Visa, Netflix & Merck

Today's Research Daily features new research reports on 16 major stocks, including Visa Inc. (V), Netflix, Inc. (NFLX) and Merck & Co., Inc. (MRK), as well as a micro-cap stock Hovnanian Enterprises, Inc. (HOV).

Kinjel Shah headshot

Merck Stock Down More Than 14% in 6 Months: Buy, Sell or Hold?

We believe you may hold MRK stock, as the company has one of the world's best-selling drugs in its portfolio that generates billions of dollars in revenues.

Gilead, MRK Report Data From Investigational Combination Study for HIV

GILD and partner MRK advance novel investigational combination regimen, a weekly oral HIV treatment, to phase III.

Merck (MRK) Rises As Market Takes a Dip: Key Facts

The latest trading day saw Merck (MRK) settling at $111.53, representing a +1.68% change from its previous close.

Exelixis, MRK Collaborate for Combination Studies on HNSCC and RCC

EXEL is set to evaluate investigational zanzalintinib in combination with Merck;s Keytruda (pembrolizumab) and Welireg in head and neck cancer and renal cell carcinoma, respectively.

Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It

Merck (MRK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Merck (MRK) Outpaces Stock Market Gains: What You Should Know

Merck (MRK) concluded the recent trading session at $110.27, signifying a +1.61% move from its prior day's close.

BMY Buoyed by Recent Regulatory Updates: How to Play the Stock?

While the recent spate of positive regulatory updates boosts Bristol Myers, we will advise a wait-and-watch strategy.

Stock Market News for Oct 4, 2024

U.S. stock markets closed lower on Thursday after a choppy session.

Merck (MRK) Dips More Than Broader Market: What You Should Know

Merck (MRK) concluded the recent trading session at $110.18, signifying a -1.7% move from its prior day's close.

Will Merck (MRK) Beat Estimates Again in Its Next Earnings Report?

Merck (MRK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Kinjel Shah headshot

Pharma Stock Roundup: JNJ's 3rd Talc-Related Bankruptcy Filing & More

JNJ files for voluntary bankruptcy for the third time. Pfizer withdraws sickle-cell drug drug Oxbryta from worldwide markets.

Merck (MRK) Stock Sinks As Market Gains: Here's Why

In the latest trading session, Merck (MRK) closed at $113.09, marking a -1.43% move from the previous day.

MRK's Keytruda Combo Fails in Phase III Colorectal Cancer Study

The phase III KEYFORM-007 study, evaluating Merck's Keytruda plus favezelimab for treating metastatic colorectal cancer, fails to meet the primary endpoint.

AZN Stock Slips as Dato-DXd Cancer Study Misses Survival Goal

AZN's Daiichi Sankyo-partnered datopotamab deruxtecan fails to show overall survival benefits in a breast cancer study. Stock falls.

Company News for Sep 24, 2024

Companies in The News Are: TSLA, DPZ, INTC, APO, MRK

EMA Committee Endorses AbbVie's Elahere in Ovarian Cancer

If approved, this will be the first regulatory approval for ABBV's Elahere in the European Union.